Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 260 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Left Ventricular Failure Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting No phase listed Observational

Pediatric Cardiomyopathy Mutation Analysis

NCT02432092
View directory record Official record
Conditions
Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Monitoring Medication Adherence in Left Ventricular Assist Device Recipients

NCT02388386
View directory record Official record
Conditions
Heart Failure, Medication Compliance
Interventions
PROTEUS-SENSOR
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial

NCT01584895
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Rehabilitation
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jul 21, 2026, 11:46 AM EDT
Terminated Phase 3 Interventional Results available

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

NCT02656329
View directory record Official record
Conditions
Heart Failure
Interventions
Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
Drug · Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional

Attain StarFix™ Model 4195 Left Ventricular Lead

NCT00269230
View directory record Official record
Conditions
Heart Failure
Interventions
Pacing Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Long Beach, California • Palo Alto, California • Newark, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

NCT00259038
View directory record Official record
Conditions
Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure, Myocardiopathies, Systolic or Diastolic Left Ventricular Dysfunction
Interventions
Carperitide, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jul 21, 2026, 11:46 AM EDT
Not yet recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional

Avicena LVDP Validation Study

NCT05633004
View directory record Official record
Conditions
Heart Failure
Interventions
Vivio
Device
Lead sponsor
Ventric Health, LLC
Industry
Eligibility
21 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Not applicable Interventional

Assessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation

NCT06682910
View directory record Official record
Conditions
Heart Failure
Interventions
Microtech sensor pressure
Device
Lead sponsor
Microtech Medical Technologies, Ltd
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 21, 2026, 11:46 AM EDT
Suspended Not applicable Interventional

Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System

NCT01187368
View directory record Official record
Conditions
Heart Failure
Interventions
EVAHEART Left Ventricular Assist System (LVAS), HeartMate 3
Device
Lead sponsor
Evaheart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
12
States / cities
Gainesville, Florida • Tampa, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed No phase listed Observational

Predicting Response to Cardiac Resynchronization Therapy in Heart Failure

NCT00359372
View directory record Official record
Conditions
Heart Failure, Left Ventricular Dysfunction
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:46 AM EDT
Withdrawn Not applicable Interventional

Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy

NCT00428103
View directory record Official record
Conditions
Mitral Valve Regurgitation, Congestive Heart Failure, Cardiomyopathy
Interventions
3 dimensional echocardiography
Procedure
Lead sponsor
Juan Crestanello, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jul 21, 2026, 11:46 AM EDT
Terminated Phase 4 Interventional Results available

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions
Exenatide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 11:46 AM EDT
Not listed No phase listed Observational

Assessment of Left Ventricular Filling Pressure by Applying Artificial Intelligence Algorithms to Left Atrial Speckle-tracking Echocardiography

NCT05768698
View directory record Official record
Conditions
Heart Failure, Diastolic, Echocardiography
Interventions
Software algorithm
Diagnostic Test
Lead sponsor
Istituto Auxologico Italiano
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

NCT04865978
View directory record Official record
Conditions
Heart Failure
Interventions
Apixaban, Warfarin, LVAD implant
Drug · Device
Lead sponsor
Palak Shah
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 4 Interventional Results available

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

NCT01936649
View directory record Official record
Conditions
Heart Failure (HF), Ventricular Dysfunction, Left
Interventions
AdreView (Iobenguane I 123 Injection)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Not applicable Interventional

Left vs Left Randomized Clinical Trial

NCT05650658
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Interventions
His/LBBP, BiVP
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
57
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 21, 2026, 11:46 AM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 21, 2026, 11:46 AM EDT